Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genentech Tissue Product Sales Stall; Rituxan Driving Immunology

Executive Summary

Sales growth has stalled for Genentech's tissue growth and repair products, with U.S. sales in the fourth quarter of 2007 nearly identical to third quarter totals. Compared to the fourth quarter of 2006, U.S. sales were down 5 percent

You may also be interested in...



Avastin Growth Not Limited To Breast Cancer In 2008, Genentech Says

Genentech anticipates continued sales growth for its blockbuster oncologic Avastin regardless of whether it is approved for first-line treatment of metastatic breast cancer

Genentech Meets With Eye Groups Protesting Avastin Sales Restrictions

Eye doctors furious over Genentech's decision to halt sales of Avastin to compounding pharmacies have succeeded in grabbing the company's attention. On Oct. 26, three of Genentech's top officers, CEO Arthur Levinson, Chief Medical Officer Hal Barron, and president of product development, Susan Desmond-Hellmann, traveled to Washington, D.C. to meet with two physician groups

Genentech Pipeline Puts Firm Ahead Of 2005 Goals, Sailing To “Horizon 2010”

As Genentech enters the final quarter of its multi-year growth plan, the firm is on track to meet or exceed the development and product approval goals set out in its "5x5" plan for the period from 1999 to 2005

UsernamePublicRestriction

Register

ID1130879

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel